A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis

Prior treatment

• Non-plaque psoriasis (ie, guttate, pustular, erythrodermic, or inverse psoriasis) within 3 months prior to baseline.
• History of a serious bacterial, fungal, or viral infection requiring hospitalization or intravenous antimicrobial therapy within 3 months prior to the first dose.
• History of a bacterial, fungal, or viral infection requiring oral antimicrobial therapy within 4 weeks prior to the first dose.
• Active infection or acute illness within 7 days prior to the first dose. Chronic or recurrent infectious diseases at screening or baseline that, in the investigator's judgment, may increase safety risks.
• History of a major or unstable clinical condition within 6 months prior to the first dose, which would compromise participation.
• Previous or current autoimmune diseases.
• Allergic to any component of the investigational drug.

Other illness

• Other skin diseases at screening or baseline Drug-induced psoriasis.
• History of severe herpes zoster or severe herpes simplex or current herpes simplex/zoster infection.
• Evidence of active TB. Patients with evidence of latent tuberculosis may enter the trial after sufficient treatment had initiated and maintained according to protocol.
• History of malignant tumour within 5 years before screening.
• Positive results of confirmatory test for hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or syphilis.

• Aged 18-75 years, willing to sign the ICF
• Diagnosed with plaque psoriasis for at least 6 months prior to screening.
• At screening and baseline, PASI score ≥ 12 points, BSA ≥ 10%, sPGA ≥ 3
• Be eligible for phototherapy or systemic therapy.